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Introduction: NASA’s Vision for Space Exploration centers on exploration class missions 
including the goals of returning to the moon and landing on Mars. One of NASA’s objectives is 
to focus research on astronaut health and the development of countermeasures that will protect 
crewmembers during long duration voyages. Exposure to microgravity affects human physiology 
and results in changes in the urinary chemical composition favoring urinary supersaturation and 
an increased risk of stone formation. Nephrolithiasis is a multifactorial disease and development 
of a renal stone is significantly influenced by both dietary and environmental factors. Previous 
results from long duration Mir and short duration Shuttle missions have shown decreased urine 
volume, pH, and citrate levels and increased calcium. Citrate, an important inhibitor of calcium-
containing stones, binds with urinary calcium reducing the amount of calcium available to form 
stones. Citrate inhibits renal stone recurrence by preventing crystal growth, aggregation, and 
nucleation and is one of the most common therapeutic agents used to prevent stone formation. 
Methods:  Thirty long duration crewmembers (29 male, 1 female) participated in this study. 24-
hour urines were collected and dietary monitoring was performed pre-, in-, and postflight. 
Crewmembers in the treatment group received two potassium citrate (KCIT) pills, 10 mEq/pill, 
ingested daily beginning 3 days before launch, all in-flight days and through 14 days postflight. 
Urinary biochemical and dietary analyses were completed. Results: KCIT treated subjects 
exhibited decreased urinary calcium excretion and maintained the levels of calcium oxalate 
supersaturation risk at their preflight levels. The increased urinary pH levels in these subjects 
reduced the risk of uric acid stones. Discussion: The current study investigated the use of 
potassium citrate as a countermeasure to minimize the risk of stone formation during ISS 
missions. Results suggest that supplementation with potassium citrate decreases the risk of stone 
formation during and immediately after spaceflight.     
 
 
https://ntrs.nasa.gov/search.jsp?R=20090019087 2019-08-30T06:50:10+00:00Z
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EVIDENCE
 As of 2008, 15 symptomatic urinary calculi have been  
experienced by 13 U.S. astronauts (Pietryzk, et al, 2006; 
Jones et al, 2008)
Multiple stone events among cosmonauts reported by 
Russian medical investigators 
 One in-flight episode nearly causing a 
mission termination but was resolved
by spontaneous stone passage
(J. Urol. 162:688, 1999; Eur Urol 24:172 1993, J Urol 152:1095, 1994; J Urol 152:1095, 1994)
10-15% in US dx’d w urolithiasis; 20-25% in Middle East.
Stones 3 mm in size can cause transient or complete obstruction.
Recurrence approx 5-10%/year up to 75% at 20 years
Spontaneous passage rates of 12%, 22%, and 45% for 
proximal, middle, and distal ureteral calculi, respectively
Urolithiasis and Stone Passage
Stone Size Chance of 
Spontaneous 
Passage
Time to Pass Stone Require surgical 
intervention
<2 mm >85% 4.5-8 days 5%
<5 mm 78-80 7 – 14.5 days 17%
5-7 mm 20-50%
(35% avg)
5.5-22 days 50%
>7 mm < 10% 
(8% avg)
53 days - never >80%
STUDY OBJECTIVES
 Quantitate the pre-, in- and postflight risk of renal stone formation 
associated with space flight.
 Determine the efficacy of potassium citrate as a countermeasure 
in reducing the in-flight and postflight for renal stone formation.
 Evaluate dietary impact on the urinary biochemistry.
 Evaluate the potential benefit of citrate to inhibit bone loss. 
 “Primum non nocere” (First Do No Harm) 
SUBJECTS
Placebo Group: n = 18
NASA-Mir missions   12 male subjects, mission duration  129 - 208 days
ISS missions               6 male subjects, mission duration 93 - 175 days 
KCIT Group: n = 12 
ISS missions 11 male/1 female subjects, mission duration 93 - 175 days 
 24-hour urines collected pre-, in-, and post-flight
 Food, fluid, exercise, and medications monitored before and
during the urine collection period
 Two potassium citrate (KCIT) pills, 10 mEq/pill, ingested daily
(with the last meal of the day) from L-3 days to R+14 days
• Double-blind study design except for last 3 ISS subjects
 Biochemical analysis of urine samples for urinary 
factors associated with stone formation
 Dietary analysis completed to assess 
environmental influences on the urinary 
biochemistry
METHODS
The majority of oral citrate is metabolized in the liver to bicarbonate, 
each citrate ion producing three bicarbonate ions.
Potassium Citrate
HCO3
pH
U-Citrate U-Calcium
Renal Stone
Effects on renal physiology
65-90% of filtered citrate is reabsorbed
10-35% of citrate is excreted into the urine
Effects of dosage used (20 mEq/d)
expected urinary increase of 130-140 mg/d
expected rise in urinary pH of 0.2 – 0.3 unitsUrinary Supersaturation
KCIT dosage of 20 mEq/d selected based on;
 results from Shuttle and NASA-Mir missions
 minimize any potential for in-flight GI upset 
(wax matrix/ slow release prep)
 minimize the potential to exaggerate the risk
for CaP stones (higher pH 7.25-7.5)
 minimize impact to crew time
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Urinary Citrate Levels
In Long Duration Crewmembers
KCIT Pills
E-FLT = Flight day <35
M-FLT = Flight day 36-120
L-FLT = Flight day >120
R+ = Postflight days
D
IE
TA
RY
 F
LU
ID
 IN
TA
K
E 
 (l
/d
)
0
1
2
3
4
5
PLACEBO
KCIT
*
*
*
* *
U
R
IN
AR
Y 
TO
TA
L 
VO
LU
M
E 
(l/
d)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
PLACEBO
KCIT
FLUID 
BALANCE
Fluid intake during flight
Low urine volumes (< 2L/d)
Similar fluid intake and total urine
volumes between groups
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Effect of Potassium Citrate on Urinary pH
Urinary pH in
KCIT crewmembers, 
but not too high
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Risk of uric acid stone
formation in KCIT 
crewmembers
Uric Acid Stones
Image from Mission Pharmacal
Effect of Potassium Citrate on Uric Acid Supersaturation
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CALCIUM
BALANCE
Dietary Ca intake below 
recommended levels
Urinary Ca excretion in KCIT
crewmembers
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Calcium Oxalate Supersaturation Data 
From Long Duration Crewmembers
Values > 2.0 indicate
increased risk
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Comparison of in-flight risk to 
individual’s preflight risk
KCIT subjects maintained calcium
oxalate risk at preflight levels
C
Risk of Calcium Oxalate
Stone Formation
 KCIT treated subjects exhibited decreased urinary calcium
excretion.
 KCIT subjects maintained the levels of calcium oxalate
supersaturation risk at their preflight levels.
 Increased urinary pH levels in KCIT treated subjects reduced the
risk of uric acid stones.
 Individual crewmember response may play a role in renal stone
susceptibility and efficacy of countermeasures.
SIGNIFICANT FINDINGS
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